CBD for rheumatoid arthritis

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis

ABSTRACT These studies demonstrate transdermal administration of CBD has long-lasting therapeutic effects without psychoactive side-effects. Thus, use of topical CBD has potential as effective treatment of arthritic symptomatology. At present, one in five (21%) adults worldwide are diagnosed with some form of arthritis by their physicians (Helmick et al., 2008). The data presented suggest transdermal …

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis Read More »

Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis

ABSTRACT This study showed for the first time that local CBD administration inhibited pain and peripheral sensitisation in established OA. Topical treatment with CBD reduced leukocyte trafficking and joint hyperaemia during the early stages of MIA. By attenuating this initial inflammatory response with CBD, end-stage OA pain and peripheral neuropathy were abrogated. Thus, CBD may …

Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis Read More »

Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis

ABSTRACT Measurement of plasma CBD concentration provided by transdermal absorption revealed linearity with 0.6–6.2 mg/day doses. Transdermal CBD gel significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose‐dependent manner. PWL recovered to near baseline level. Immunohistochemical analysis of spinal …

Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis Read More »

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

ABSTRACT The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. …

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Read More »

Scroll to Top
Scroll to Top